Table of Contents Table of Contents
Previous Page  121 / 154 Next Page
Information
Show Menu
Previous Page 121 / 154 Next Page
Page Background

A B S T R A C T S

S91

older patients with cancer warranting a complete geriatric

assessment.

Reference:

[1] Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, et al.

Optimizing the G8 Screening Tool for Older Patients With

Cancer: Diagnostic Performance and Validation of a Six-

ItemVersion. Oncologist 2016; 21(2): 188-95.

Disclosure of interest:

None declared

Keywords:

Geriatric assessment, gold standard, screening

tools, vulnerability

P093

A RANDOMIZED CONTROLLED TRIAL OF GERIATRIC

ASSESSMENT GUIDED MULTIDISCIPLINARY

INTERVENTIONS: THE FIRST YEAR EXPERIENCE

D. Li

1,

*, C. Kelly

1

, M. Trent

1

, M. Fakih

1

, M. Koczywas

1

,

M. Cristea

1

, S. Pal

1

, V. Chung

1

, J. Mortimer

1

, Y. Yuan

1

,

P. Burhenn

1

, V. Katheria

1

, D. Rivera

1

, G. Varatkar

1

, K. Yu

1

,

S. Hite

1

, D. Mitani

1

, B. Ferrell

1

, A. Hurria

1

1

City of Hope, Duarte, USA

Introduction:

Geriatric assessment (GA) can predict

chemotherapy toxicity and identify potential interventions in

older adults with cancer.The National Comprehensive Cancer

Network and the International Society for Geriatric Oncology

currently recommends incorporating the use of GA and GA-

guided interventions in the care of older cancer patients.

Objectives:

The overall goal of this study is to determine the

effect of GA-guided multidisciplinary interventions in the care

of older adults with cancer beginning a new chemotherapy

regimen. In this abstract we describe the first year experience

of this randomized controlled trial.

Methods:

In this randomized controlled trial, 600 patients

age

65 with a diagnosis of solid tumor malignancy will be

randomized to GA intervention or standard of care in a 2:1

randomization. All patients complete a GA (Hurria et al.

Journal of Clinical Oncology 2016) prior to initiation of a new

chemotherapy regimen and a Cancer and Aging Research

Group (CARG) chemotherapy toxicity score is generated.

Patients randomized to the GA intervention arm have their

assessment results reviewed and summarized to form an

intervention plan. The results of the GA and intervention

recommendations are reviewed by a multidisciplinary team.

These recommendations are provided to the oncologist and

patient and then implemented by the study nurse. Patients

with a chemotherapy toxicity risk score

50% are co-managed

with the study nurse who has geriatric oncology expertise.

Patients randomized to the standard of care armalso complete

a GA, which is provided to their treating oncologist and nurse

for review. Grade 3-5 treatment-related toxicity (NCI CTCAE

v4.0), dose reductions or delays, emergency room visits and

unplanned hospitalizations are captured during treatment.

Results:

The study began in August 2015 and 21 physicians

throughout the Department of Medical Oncology enrolled

patients to the study. Out of 173 potentially eligible patients,

136 (79%) have enrolled. Participants had a median age of 72

(range 65-92) with gastrointestinal (28%), breast (22%), lung

(21%), genitourinary (17%), gynecological (7%), and other

types (5%) of malignancies. A majority of patients had stage

IV disease (84%). A CARG chemotherapy toxicity score was

generated for all patients: 30% low risk (N=40), 43% medium

risk (N=59), and 27% high risk (N=37). Based on GA results,

referrals to members of a multidisciplinary team were

recommended to 122/136 (90%) patients.A total of 395 referrals

to the following members of the multidisciplinary team were

made: 20% nutrition (N=78), 17% occupational therapy (N=67),

17% physical therapy (N=67), 16% social work (N=63), 15%

pharmacy (N=60), 5% chaplain (N=19), 1% neurology (N=6),

and 9% other (N=35).

Conclusion:

A high proportion of eligible patients enrolled

onto this prospective randomized controlled trial. Based on

GA results, referrals to members of the multidisciplinary team

were common. The large number of referrals indicates the

high level of medical burden among older adults with cancer.

The utility of a GA-guided multidisciplinary intervention to

decrease hospitalizations and toxicity will be determined

upon completion of this randomized controlled trial.

Disclosure of interest:

D. Li: None declared, C. Kelly: None

declared, M. Trent: None declared, M. Fakih: None declared,

M. Koczywas: None declared, M. Cristea: None declared, S.

Pal: None declared, V. Chung Speakers bureau: Celgene, J.

Mortimer: None declared, Y. Yuan: None declared, P. Burhenn:

None declared, V. Katheria: None declared, D. Rivera: None

declared, G. Varatkar: None declared, K. Yu: None declared,

S. Hite: None declared, D. Mitani: None declared, B. Ferrell:

None declared, A. Hurria Grant/Research Support from:

Celgene, Novartis, GSK, Consultant for: Boehringer Ingelheim

Pharmaceuticals, Carevive, Sanofi, GTx Inc.

Keywords:

Chemotherapy, geriatric assessment,

multidisciplinary interventions

P095

EVALUATION OF THE G8, VES-13 AND FRIED FRAILTY

CRITERIA AS SCREENING TOOLS FOR MULTIDIMENSIONAL

HEALTH PROBLEMS IN PATIENTS ENROLLED IN A PHASE

II TRIAL OF GERIATRIC ASSESSMENT AND MANAGEMENT

FOR OLDER ADULTS WITH CANCER

D. W. Yokom

1,

*, S. Alibhai

2,3

, M. Puts

4

1

Division of Medical Oncology,

2

Department of Medicine, University

of Toronto,

3

Department of Medicine, University Health Network,

4

Lawrence S. Bloomberg Faculty of Nursing, University of Toronto,

Toronto, Canada

Introduction:

Screening tools are important aides for

oncologists to quickly identify older adults with cancer

who are at increased risk of toxicity, functional decline and

death and who could benefit from a comprehensive geriatric

assessment (CGA). These screening tools have not previously

been described for prediction of CGA-based interventions.

Objectives:

To assess the performance of the G8, VES-13,

and modified Fried Frailty Criteria (FFC) as screening tools for

an abnormal CGA or CGA-based medical interventions.